Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Sabrina Porta, Alvaro Danza, Maira Arias Saavedra, Adriana Carlomagno, María Cecilia Goizueta, Florencia Vivero and Guillermo Ruiz-Irastorza
- Rheumatology Department, Hospital JM Ramos Mejía, Buenos Aires 1221, Argentina; psachu@gmail.com (S.P.); mairaariassaavedra@gmail.com (M.A.S.)
- Department of Internal Medicine, Faculty of Medicine, Universidad de la República,
Montevideo 11000, Uruguay; alvarodanza@gmail.com (A.D.); adrianacarlomagno@gmail.com (A.C.) - Autoimmune Disease Unit, Sanatorio 9 de Julio, Tucumán T4000, Argentina; cecigoizueta@yahoo.com.ar
- Autoimmune Disease Unit, Hospital Privado de Comunidad, Mar del Plata B7600, Argentina; florenciavivero82@gmail.com
- Autoimmune Diseases Research Unit, BioCruces Bizkaia Health Research Institute, Cruces Univeristy Hospital, 48903 Bizkaia, Spain
- University of the Basque Country, 48940 Leioa, Spain
* Correspondence: r.irastorza@outlook.es
Received: 9 July 2020; Accepted: 17 August 2020; Published: 21 August 2020